(Q43036906)

English

The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr.

scientific article published on 31 March 2007

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Maria Rosaria Capobianchi

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Francesco Vairo

object named as

Francesco Vairo

4

0 references

author name string

Giorgio Antonucci

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Maria Antonella Longo

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Claudio Angeletti

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Alessandra Oliva

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ubaldo Visco Comandini

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Evangelo Boumis

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Pasquale Noto

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Maria Carmela Solmone

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

31 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

102

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1383-1391

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Diagnosis, management, and treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Chronic hepatitis C virus infection in older adults

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Incident hepatitis C virus infection in a community-based population in Japan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Factors contributing to ribavirin-induced anemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Ageing of lymphocytes and lymphocytes in the aged

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Age-related changes in lymphocyte development and function

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

The pattern of T lymphocyte differentiation is altered during thymic involution

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Effect of aging on T lymphocyte activation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Altered T cell signalling in ageing

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01201.X

21 January 2018

Identifiers

10.1111/J.1572-0241.2007.01201.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43036906&oldid=1590009536"